Ex-Pfizer exec Gutiérrez-Ramos heads to startup Synlogic

After leaving Pfizer ($PFE) earlier this month as chief of biotherapeutic research,José-Carlos Gutiérrez-Ramos landed back in biotech this week as head of Synlogic, a startup focused on finding a novel approach to drug development. The company was backed about a year ago by Atlas Venture and New Enterprise Associates to the tune of $29.4 million, and plans to get started with a proprietary approach to synthetic biology, first focusing on rare diseases. During his time with Pfizer, Gutiérrez-Ramos led more than 25 projects, and prior to that, he headed development work at GlaxoSmithKline ($GSK) and Millennium Pharmaceuticals. “Synlogic has assembled an outstanding team of founders, scientists, collaborators and investors to make the potential of synthetic biology a reality for the treatment of human disease,” Gutiérrez-Ramos said in a statement. “I am thrilled to lead them in this fascinating journey to change the world by bringing the future of medicine forward.”



Leave a Reply